ライフサイエンスコーパス: respiratory insufficiency

1 equently, neonatal pups died at birth due to respiratory insufficiency.

2 e oxygen/RS is a better indicator of chronic respiratory insufficiency.

3 the lungs, causing DAD and leading to acute respiratory insufficiency.

4 pleural effusion and clinically as hypoxemic respiratory insufficiency.

5 bulbar palsy, sensorineural hearing loss and respiratory insufficiency.

6 ower limbs), hearing loss, optic atrophy and respiratory insufficiency.

7 and sensorimotor neuropathy with or without respiratory insufficiency.

8 th in severe cases as a result of associated respiratory insufficiency.

9 o WNV-infected or sham-infected mice without respiratory insufficiency.

10 zed by muscle weakness, spinal rigidity, and respiratory insufficiency.

11 tients had lethargy, 1 had ataxia, and 1 had respiratory insufficiency.

12 tance data to identify protein biomarkers of respiratory insufficiency.

13 ine myopathy that is fatal in infancy due to respiratory insufficiency.

14 d fever, myalgias, progressive weakness, and respiratory insufficiency.

15 is feasible for noninvasive therapy of acute respiratory insufficiency.

16 r only slowly progressive weakness and early respiratory insufficiency.

17 ss the protein and they die perinatally from respiratory insufficiency.

18 ical and dorso-lumbar regions, scoliosis and respiratory insufficiency.

19 tion (VV-ECMO) in patients with severe acute respiratory insufficiency.

20 espite therapeutic optimisation, she died of respiratory insufficiency.

21 ts (597/875; 68%) had a primary diagnosis of respiratory insufficiency.

22 , fluctuating creatine kinase elevation, and respiratory insufficiency.

23 , neck and spine contractures, hypotonia and respiratory insufficiency.

24 verse events such as anastomotic leakage and respiratory insufficiency.

25 (62.5%) had lost ambulation, 14 (93.3%) had respiratory insufficiency (11 requiring ventilation) and

26 (4% versus 1%), pneumonitis (8% versus 4%), respiratory insufficiency (13% versus 8%), transient cen

27 deaths in the validation cohort were due to respiratory insufficiency, 14 percent to myocardial infa

28 is most often cardiac (50%-60%), followed by respiratory insufficiency (15%-40%).

29 , renal failure (0.44% versus 0.29%; P=0.6), respiratory insufficiency (3.5% versus 3.8%; P=0.7), and

30 Hypertrophic cardiomyopathy (9 [53%]) and respiratory insufficiency (8 [47%]) were also prominent

31 ung, leading to a frequently lethal triad of respiratory insufficiency, acute cardiovascular failure,

32 sease with increased prevalence of prolonged respiratory insufficiency, acute kidney injury, sepsis,

33 One patient died of respiratory insufficiency after a laparotomy.

34 COVID-19 pandemic, the frequency of chronic respiratory insufficiency after acute SARS-CoV-2 infecti

35 sorders, such as obstructive sleep apnea, or respiratory insufficiency after spinal injury or during

36 ies for treating breathing disorders such as respiratory insufficiency after spinal injury.

37 The p.F93del mutation results in respiratory insufficiency and loss of complex I stabilit

38 opmental delay, confinement to a wheelchair, respiratory insufficiency and premature death.

39 able, usually includes progressive hypoxemic respiratory insufficiency and, in some patients, seconda

40 resented with severe hypotonia, bradycardia, respiratory insufficiency, and heart failure; two sister

41 zed by accumulation of pulmonary surfactant, respiratory insufficiency, and increased infections.

42 t more likely to have renal failure, sepsis, respiratory insufficiency, and receive mechanical ventil

43 rash, marked osteopenia, lytic bone lesions, respiratory insufficiency, and thrombosis.

44 infections contribute to lung tissue damage, respiratory insufficiency, and ultimately death in the p

45 delay with pronounced generalized hypotonia, respiratory insufficiency, and variable neurodegeneratio

46 ises arthrogryposis, spontaneously resolving respiratory insufficiency at birth, muscular atrophy pre

47 Currently available treatments for DMD respiratory insufficiency attenuate respiratory symptoms

48 akness of proximal dominance, hypotonia, and respiratory insufficiency but typically not cardiac dysf

49 d survival by limiting deaths resulting from respiratory insufficiency, but there is currently no eff

50 greater distally than proximally, as well as respiratory insufficiency, cardiomyopathy, and cervical

51 soon after birth, apparently as a result of respiratory insufficiency caused by rib and sternum defe

52 Egr2-null mice die perinatally of respiratory insufficiency characterized by subnormal res

53 ) is susceptible to fibrosis and the ensuing respiratory insufficiency contributes to significant mor

54 he presence of eosinophils in cases of acute respiratory insufficiency due to diffuse alveolar damage

55 severe gait ataxia, spinal deformities, and respiratory insufficiency due to neuromuscular incoordin

56 Severely affected babies often die from respiratory insufficiency due to progressive chest defor

57 They were previously well before developing respiratory insufficiency due to severe COVID-19, requir

58 admission diagnoses were sepsis (21.5%) and respiratory insufficiency/failure (25.7%).

59 children who have varying degrees of chronic respiratory insufficiency from many causes.

60 ential sequelae to even mild or intermittent respiratory insufficiency have been identified.

61 nophilic pneumonia is characterized by acute respiratory insufficiency, hypoxemia, fever, diffuse rad

62 research findings on the pathophysiology of respiratory insufficiencies in DMD disease in humans and

63 ic pleural effusion in 366 (30.1%) patients, respiratory insufficiency in 141 (11.6%), acute respirat

64 ALS, which validated against the outcome of respiratory insufficiency in an external cohort.

65 may inspire novel therapeutic strategies for respiratory insufficiency in diverse conditions, such as

66 eome that either directly underly or predict respiratory insufficiency in mutator mice.

67 get in developing therapeutic strategies for respiratory insufficiency in patients with, for example,

68 nd that projected group membership predicted respiratory insufficiency in the PRO-ACT cohort (concord

69 ced development of cardiomyopathy and severe respiratory insufficiency in their teens; two had rigid

70 To explore the possibility that neurological respiratory insufficiency is a broad mechanism of death

71 Respiratory insufficiency is the leading cause of death

72 ough, atelectasis and pneumonia, and chronic respiratory insufficiency leading to respiratory failure

73 We assessed in health centres respiratory insufficiency, low back pain, degree of phys

74 Beside respiratory insufficiency, many hospitalized patients ex

75 interventions were IV sodium chloride before respiratory insufficiency (n = 17), IV sodium chloride a

76 fficiency (n = 17), IV sodium chloride after respiratory insufficiency (n = 22), and fluid restrictio

77 Respiratory insufficiency occurred in two of these patie

78 opment or steroidogenesis) are not born with respiratory insufficiency or abnormal lung development,

79 al because they lacked significant weakness, respiratory insufficiency, or scoliosis.

80 Quadriplegia, quadriparesis, or respiratory insufficiency persisted after the first week

81 tients who received IV sodium chloride after respiratory insufficiency, plasma sodium levels were inc

82 ients who received IV sodium chloride before respiratory insufficiency, plasma sodium levels were inc

83 l course was characterized by progression of respiratory insufficiency, pleural effusions and pulmona

84 The predominant reasons for admission were respiratory insufficiency, postoperative care, and heart

85 els display similar perinatal lethality with respiratory insufficiency, reduced body weight and lengt

86 Thirty-four patients with 35 episodes of respiratory insufficiency requiring airway support or ox

87 p < 0.001), and presenting with less chronic respiratory insufficiency requiring home mechanical vent

88 a CNS event of unknown cause and pneumonia, respiratory insufficiency resulting from an neuromyeliti

89 of a severely constricted thoracic cage and respiratory insufficiency; retinal degeneration, cystic

90 BS) and to simplify the existing Erasmus GBS Respiratory Insufficiency Score (EGRIS) for predicting t

91 validate the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score in the International Gui

92 The Erasmus GBS Respiratory Insufficiency Score is a validated tool usef

93 alidated the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score, and showed that the mod

94 on indications in patients with ACS included respiratory insufficiency, shock, or the need for vasoac

95 Neurological respiratory insufficiency strongly correlates with morta

96 entilatory control disorders associated with respiratory insufficiency, such as spinal injury and mot

97 respiratory neuroplasticity in disorders of respiratory insufficiency suggests that membrane estroge

98 lowly declines, and skeletal deformities and respiratory insufficiency supervene.

99 produces a dramatic neuromotor syndrome and respiratory insufficiency that often necessitate intensi

100 Here we show, in a porcine model of varied respiratory insufficiency, that a contractile soft robot

101 ely study clinical and radiological PPCs and respiratory insufficiency therapies in a high-risk surgi

102 sive muscle weakness, joint contractures and respiratory insufficiency, to Bethlem muscular dystrophy

103 deformity develop before the children die of respiratory insufficiency, usually in the second year.

104 Adult patients with acute respiratory insufficiency were randomized to receive NPP

105 however, these died shortly after birth from respiratory insufficiency, without primary cardiopulmona